UK MHRA Aims To Address "Fundamental Failures" In Data Integrity
Executive Summary
The UK MHRA's revised guidance on maintaining the integrity of data throughout the chemical and pharmaceutical development lifecycle is intended to address various shortcomings identified by regulators during inspections.
You may also be interested in...
49 PIC/S Inspectorates Test-Drive Data Integrity Guidance
Pharmaceutical Inspection Cooperation Scheme member inspectorates are trying out the most comprehensive manufacturing data integrity guidance yet developed. Issued amid a flurry of guidance from various authorities, it could play a key role in harmonizing regulatory approaches.
EMA Clarifies Compliance With ALCOA Principles Is Key To Meeting Data Integrity Expectations
The EMA's guidance on data integrity expectations focuses on good manufacturing practice requirements and offers advice on minimizing risks at all stages of the data lifecycle in pharmaceutical quality systems.
WHO Tackles Submission Of Insufficient Or False Data By Pharma
The World Health Organization has developed what it claims is the first comprehensive guidance document on data integrity that should help regulatory authorities and inspectors identify instances of pharmaceutical companies submitting insufficient or false data1.